recruiting into or retaining participants in scientific studies.

E. Dissemination of Research Results

Externally awarded investigators are urged to make special efforts to disseminate relevant research results to the communities who participated in the studies and to the populations to which they pertain, especially racial and ethnic minority populations which may have cultural, language, and socioeconomic barriers to the easy receipt of such information.

VI. Evaluation

CDC Inclusion Review Committee Responsibility and Members

A CDC Inclusion Review Committee (IRC) with representatives from the CDC Office of the Associate Director for Science, the CDC Office of the Associate Director for Minority Health, and the CDC Office of the Associate Director for Women's Health will review any questions, issues, or comments pertaining to this policy and recommend necessary changes or modifications to the Director, CDC. This committee will meet regularly to review compliance with this policy and evaluate the impact of this policy on research activities at CDC. The CDC IRC may periodically conduct random audits of research protocols to assess compliance with this policy.

Dated: March 30, 1995.

Claire V. Broome,

Deputy Director, Centers for Disease Control and Prevention (CDC) and Deputy Administrator, Agency for Toxic Substances and Disease Registry (ATSDR). [FR Doc. 95–8718 Filed 4–7–95; 8:45 am] BILLING CODE 4163–18–P

[Announcement 525]

Continuation of the Development of Technology for the Measurement of Lead in Blood; Notice of Availability of Funds for Fiscal Year 1995

Introduction

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 1995 funds for a grant program for the continuation of the development of new and innovative technology, or significant improvement of existing technology, for the measurement of lead in blood. CDC has supported such development efforts under a grant program since FY 1992 and under Cooperative Research and Development Agreements (CRADAs) since 1991. State, community and physician officebased childhood lead poisoning prevention programs have a need for reasonably priced, accurate, precise, portable, rugged, and easy-to-operate instruments or analytical techniques to measure the concentration of lead in blood. Such programs screen large numbers of infants and young children and identify those with lead poisoning.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity to reduce morbidity and mortality and improve the quality of life. This announcement is related to the priority area of Environmental Health. (For ordering a copy of "Healthy People 2000," see the section **Where To Obtain Additional Information**.)

Authority

This program is authorized under sections 301(a) [42 U.S.C. 241(a)] and 317B(b) [42 U.S.C. 247b-3(b)] of the Public Health Service Act, as amended.

Smoke-Free Workplace

PHS strongly encourages all grant recipients to provide a smoke-free workplace and to promote the nonuse of all tobacco products, and Public Law 103–227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, and early childhood development services are provided to children.

Eligible Applicants

Eligible applicants are limited to those organizations which are currently developing innovative technology for the measurement of lead in blood, funded under CDC grant Announcement 269 (included in the application package), or organizations which have a current CDC Cooperative Research and Development Agreement (CRADA) dealing with blood lead measurement technology. However, if funded, the CDC CRADA dealing with blood lead will be terminated.

Note: Eligible applicants are encouraged to enter into contracts, including consortia agreements, as necessary to meet the requirements of the program and strengthen the overall application.

Availability of Funds

Approximately \$800,000 is available in FY 1995 to fund up to three grants. It is expected that the average award will be \$250,000, ranging from \$100,000 to \$500,000. It is expected that the awards will begin on or about June 30, 1995, and will be made for a 12-month budget period within a project period of up to one year. Funding estimates may vary and are subject to change.

Purpose

State and community health agencies are the principal delivery points for childhood lead screening and related medical and environmental management activities. Universal screening of children is recommended in "Preventing Lead Poisoning in Young Children-a Statement by the Centers for Disease Control," (October 1991); however, the lack of analytical systems (methods plus instrumentation) which are easy-to-operate, rugged, and suitable for field use in screening programs have made it difficult and costly for agencies to develop programs for the elimination of this totally preventable disease. This program will provide financial support for the continuation and possible completion of the development and validation of new and innovative technology leading to better blood lead measurement systems.

Program Requirements

The following are essential requirements of the Grantee:

1. Provide a principal investigator with the authority, responsibility, and research experience to carry out the objectives of the grant.

2. Provide qualified staff, laboratory and/or production facilities, equipment, and other resources necessary to carry out the objectives of the grant.

3. Conduct a scientifically sound, goal-oriented research and development program which will yield all or portions of practical analytical systems which measure one or more chemicals in complex solutions. Understand and address the difficult analytical problem presented by a blood sample matrix.

4. Publish the results of the research effort in the peer-reviewed scientific literature, or otherwise make the research findings available for objective evaluation and use.

5. Provide evidence of significant progress under the previous grant or CRADA for blood lead measurement technology consistent with the goals and objectives of the original grant or CRADA, and clearly show that successful completion could be reasonably expected within the one year project period.

Evaluation Criteria

The applications will be reviewed and evaluated according to the following criteria:

1. Understanding of the Problem (30%)

By progress under previous grant or CRADA agreement, the Applicant has